After 24 weeks of RA treatment, an increase in PCSK9 levels was observed with glucocorticoid plus methotrexate treatment, while PCSK9 levels remained largely unchanged in patients treated with certolizumab pegol plus methotrexate, abatacept plus methotrexate or tocilizumab plus methotrexate. The gene discussed is PCSK9; the disease is rheumatoid arthritis.